| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 365 (9472), 1687-1717, 2005 | 7818 | 2005 |
| Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 366 (9503), 2087-2106, 2005 | 6204 | 2005 |
| Tamoxifen for early breast cancer: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 351 (9114), 1451-1467, 1998 | 3975 | 1998 |
| Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 … Early Breast Cancer Trialists' Collaborative Group The Lancet 378 (9804), 1707-1716, 2011 | 3892 | 2011 |
| Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials EBCTC Group The lancet 378 (9793), 771-784, 2011 | 3045 | 2011 |
| Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer A Howell, J Cuzick, M Baum, A Buzdar, M Dowsett, JF Forbes, ... Lancet 365 (9453), 60-62, 2005 | 2949 | 2005 |
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials EBCTC Group The Lancet 379 (9814), 432-444, 2012 | 2221 | 2012 |
| Trastuzumab emtansine for residual invasive HER2-positive breast cancer G Von Minckwitz, CS Huang, MS Mano, S Loibl, EP Mamounas, M Untch, ... New England Journal of Medicine 380 (7), 617-628, 2019 | 2220 | 2019 |
| Polychemotherapy for early breast cancer: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 352 (9132), 930-942, 1998 | 2150 | 1998 |
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC … A The The Lancet 359 (9324), 2131-2139, 2002 | 2087 | 2002 |
| Palbociclib in hormone-receptor–positive advanced breast cancer NC Turner, J Ro, F André, S Loi, S Verma, H Iwata, N Harbeck, S Loibl, ... New England Journal of Medicine 373 (3), 209-219, 2015 | 1700 | 2015 |
| Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer G Von Minckwitz, M Procter, E De Azambuja, D Zardavas, M Benyunes, ... New England Journal of Medicine 377 (2), 122-131, 2017 | 1487 | 2017 |
| 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years H Pan, R Gray, J Braybrooke, C Davies, C Taylor, P McGale, R Peto, ... New England Journal of Medicine 377 (19), 1836-1846, 2017 | 1447 | 2017 |
| Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 386 (10001), 1341-1352, 2015 | 1313 | 2015 |
| Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 355 (9217), 1757-1770, 2000 | 1273 | 2000 |
| Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer Early Breast Cancer Trialists' Collaborative Group New England journal of medicine 319 (26), 1681-1692, 1988 | 1063 | 1988 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 974 | 2018 |
| Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial D Tripathy, SA Im, M Colleoni, F Franke, A Bardia, N Harbeck, SA Hurvitz, ... The lancet oncology 19 (7), 904-915, 2018 | 918 | 2018 |
| Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer: results of the ATAC … ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group Cancer 98 (9), 1802-1810, 2003 | 900 | 2003 |
| Overall survival with ribociclib plus fulvestrant in advanced breast cancer DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... New england Journal of medicine 382 (6), 514-524, 2020 | 673 | 2020 |
Sabino De PlacidoProfessore Ordinario di Oncologia Medica在 unina.it 的电子邮件经过验证
